why choose us

First received: May 24, 2023

Clinical Trial: Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neovascular Age-related Macular Degeneration

Study Type: INTERVENTIONAL


Official Title: ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration

Brief Summary: Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy.Only one eye will be chosen as the study eye.

Read more